

603567

2021-001

	65
	2021 6 15 21:00-22:00
	ImmunoMedics / CTO Morris  IR
	2021 6 16  , 2021 6 15 App  1.

	1996	2015	A
	2006	2014	2019
	3	50	3
2.			
1	1982		30
2			

Morris

1

cGMP

4x5000L=20000L

2

500

25-33

15

Orencia Belatacept

Remicade Stelera Golimumab Brentuximab  
FactorVIII Bynllysta  
Retuxan Herceptin Perjeta Kadcylla Ocrevus Polyvi  
Tecentriq  
50

PD-1

3

ADC

Brentuximab, Kadcyla, Her2ADC  
ImmunoMedics Sacituzumab Trop2ADC)

ADC

1993

Linker

4

3-8g

60

5

5

/

Morris Rosenberg, Sandeep Gupta)

Asana (NJ, US) Ardeagen Seattle,

US

5

a.

A

b.

FDA

Ardeagen Asana

c.

**Morris**

2008

ADC

Seattle Genetics

ADC

2012

1

2)

3

FDA

Ardeagen

Ardeagen

Ardeagen

ADC

30

10

ADC

10

ADC

ADC

ADC

ADC

Morris

ADC

FDA

I/III

FDA



1	GoldenPineFund	ShuLi	33		
2	MightyDivineInvestmentManagementLimited	HongLiu	34		